

IN THE CLAIMS

1. (Canceled)
2. (Currently amended) The medical article of Claim Claim 4-11, wherein the medical article is a stent.
3. (Currently amended) The medical article of Claim Claim 4-11, wherein block A comprises the biological moiety, and block B comprises the structural moiety.
4. (Currently amended) The medical article of Claim Claim 4-11, wherein block B comprises the biological moiety, and block A comprises the structural moiety.
5. (Currently amended) The medical article of Claim Claim 4-11, wherein the biological moiety is selected from a group consisting of poly(alkylene glycols), poly(ethylene oxide), poly(ethylene oxide-co-propylene oxide), poly(N-vinyl pyrrolidone), poly(acrylamide methyl propane sulfonic acid) and salts thereof, sulfonated dextran, polyphosphazenes, poly(orthoesters), poly(tyrosine carbonate), hyaluronic acid, hyaluronic acid having a stearoyl or palmitoyl substituent group, poly(ethylene glycol)-hyaluronic acid, poly(ethylene glycol)-hyaluronic acid-stearoyl, poly(ethylene glycol)-hyaluronic acid-palmitoyl, heparin, poly(ethylene glycol)-heparin, and copolymers thereof.
6. (Currently amended) The medical article of Claim Claim 4-5, wherein the poly(alkylene glycol) is selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene glycol), a graft copolymer of poly(L-lysine) and poly(ethylene glycol), and copolymers thereof.
7. (Canceled).
8. (Currently amended) The medical article of Claim Claim 4-11, wherein the block copolymer is selected from a group consisting of poly(ethylene-glycol)-block-

poly(butylene terephthalate)-block-poly(ethylene-glycol), poly(butylene terephthalate)-block-poly(ethylene-glycol)-block poly(butylene terephthalate), poly(ethylene-glycol)-block-poly(butylene terephthalate), poly(ethylene-glycol)-block-poly(lactic acid)-block-poly(ethylene-glycol), poly(lactic acid)-block-poly(ethylene-glycol)-block-poly(lactic acid) and blends thereof.

9. (Currently amended) The medical article of Claim ~~Claim 4-11~~, additionally comprising a first biologically active agent incorporated into the coating.

10. (Currently amended) The medical article of Claim ~~Claim 4-11~~, additionally comprising an active agent conjugated to the block copolymer.

11. (Currently amended) ~~The A~~ medical article of ~~Claim 10, comprising an implantable substrate having a coating, the coating including an ABA or an AB block copolymer, the block copolymer having A and B blocks and an active agent conjugated to the block copolymer,~~

wherein one of the blocks comprises a biological moiety and the other block comprises a structural moiety that provides the block copolymer with structural functionality,

wherein the structural moiety comprises poly(butylene terephthalate), poly(ester amide), poly(lactic acid), or copolymers thereof, and

wherein the active agent conjugated to the block copolymer is diazenium diolate.

12. (Canceled)

13. (Currently amended) The method of ~~Claim 12-22~~, wherein the medical article is a stent.

14. (Currently amended) The method of ~~Claim 12-22~~, wherein block A comprises the biological moiety, and block B comprises the structural moiety.

15. (Currently amended) The method of ~~Claim 12-22~~, wherein block B comprises the

biological moiety, and block A comprises the structural moiety.

16. (Currently amended) The method of Claim 12-22, wherein the biological moiety is selected from a group consisting of poly(alkylene glycols), poly(ethylene oxide), poly(ethylene oxide-co-propylene oxide), poly(N-vinyl pyrrolidone), poly(acrylamide methyl propane sulfonic acid) and salts thereof, sulfonated dextran, polyphosphazenes, poly(orthoesters), poly(tyrosine carbonate), hyaluronic acid, hyaluronic acid having a stearoyl or palmitoyl substituent group, poly(ethylene glycol)-hyaluronic acid, poly(ethylene glycol)-hyaluronic acid-stearoyl, poly(ethylene glycol)-hyaluronic acid-palmitoyl, heparin, poly(ethylene glycol)-heparin, and copolymers thereof.

17. (Currently amended) The method of Claim 16-22, wherein the poly(alkylene glycol) is selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene glycol), a graft copolymer of poly(L-lysine) and poly(ethylene glycol), and copolymers thereof.

18. (Canceled).

19. (Currently amended) The method of Claim 12-22, wherein the block copolymer is selected from a group consisting of poly(ethylene-glycol)-block-poly(butyleneterephthalate)-block-poly(ethylene-glycol), poly(butyleneterephthalate)-block-poly(ethylene-glycol)-block poly(butyleneterephthalate), poly(ethylene-glycol)-block-poly(butyleneterephthalate), poly(ethylene-glycol)-block-poly(lactic acid)-block-poly(ethylene-glycol), poly(lactic acid)-block-poly(ethylene-glycol)-block-poly(lactic acid) and blends thereof.

20. (Currently amended) The method of Claim 12-22, additionally comprising a first biologically active agent incorporated into the coating.

21. (Currently amended) The ~~medical article~~ method of Claim 12-22, additionally

comprising an active agent conjugated to the block copolymer.

22. (Currently amended) The medical article of Claim 21, A method for fabricating a medical article, the method including applying a coating on at least a portion of an implantable substrate, the coating including an ABA or an AB block copolymer, the block copolymer having A and B blocks and an active agent conjugated to the block copolymer,
wherein one of the blocks comprises a biological moiety and the other block comprises a structural moiety that provides the block copolymer with structural functionality,
wherein the structural moiety comprises poly(butylene terephthalate), poly(ester amide),
poly(lactic acid), or copolymers thereof, and
wherein the active agent conjugated to the block copolymer is diazenium diolate.

23. (Currently amended) The medical article of Claim 4-11, wherein the coating further comprises phosphoryl choline or polyaspirin.